Encompass Health (NYSE:EHC) Posts Earnings Results

Encompass Health (NYSE:EHC) released its quarterly earnings results on Wednesday. The company reported $1.12 EPS for the quarter, topping the consensus estimate of $0.93 by $0.19, Briefing.com reports. Encompass Health had a return on equity of 17.69% and a net margin of 7.33%. The company had revenue of $1.32 billion during the quarter, compared to analyst estimates of $1.27 billion. During the same quarter last year, the business posted $0.88 earnings per share. The firm’s revenue was up 13.4% on a year-over-year basis. Encompass Health updated its FY24 guidance to $3.86-4.11 EPS.

Encompass Health Trading Down 0.9 %

NYSE:EHC traded down $0.73 during trading hours on Thursday, reaching $82.07. 397,230 shares of the company were exchanged, compared to its average volume of 658,610. Encompass Health has a 52-week low of $57.55 and a 52-week high of $85.84. The firm has a market cap of $8.22 billion, a price-to-earnings ratio of 23.57, a PEG ratio of 1.53 and a beta of 0.94. The company has a debt-to-equity ratio of 1.19, a current ratio of 1.28 and a quick ratio of 1.28. The stock has a 50 day simple moving average of $77.89 and a 200 day simple moving average of $70.67.

Encompass Health Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Monday, April 1st were given a dividend of $0.15 per share. The ex-dividend date of this dividend was Thursday, March 28th. This represents a $0.60 dividend on an annualized basis and a yield of 0.73%. Encompass Health’s dividend payout ratio (DPR) is currently 17.29%.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on EHC shares. Truist Financial upped their target price on Encompass Health from $82.00 to $86.00 and gave the stock a “buy” rating in a report on Friday, February 9th. Barclays increased their price objective on Encompass Health from $95.00 to $101.00 and gave the company an “overweight” rating in a report on Thursday, March 28th. Stephens reissued an “overweight” rating and set a $85.00 target price on shares of Encompass Health in a research note on Tuesday, January 16th. Mizuho raised their target price on shares of Encompass Health from $93.00 to $95.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $83.00 price target on shares of Encompass Health in a report on Friday, February 9th. Eight research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $84.67.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.